JANSSEN-CILAG, S.A. secures contract for Various medicinal products Award of the Specific Contract for the Medicine AMIVANTAMAB 350 MG CONCENTRATE FOR SOLUTION AMIVANTAMAB 1600 MG INJECTABLE SOLUTION AND AMIVANTAMAB 2240 MG INJECTABLE SOLUTION derived from the Dynamic Acquisition System for the Supply of Exclusive Medicines for the Consorci Sanitari de Terrassa

Spain, June 8 -- Spain based JANSSEN-CILAG, S.A. has secured contract from Consorci Sanitari de Terrassa for Various medicinal products Award of the Specific Contract for the Medicine AMIVANTAMAB 350 MG CONCENTRATE FOR SOLUTION AMIVANTAMAB 1600 MG INJECTABLE SOLUTION AND AMIVANTAMAB 2240 MG INJECTABLE SOLUTION derived from the Dynamic Acquisition System for the Supply of Exclusive Medicines for the Consorci Sanitari de Terrassa . The value of the contract is worth 27813780 EUR .

Published by HT Digital Content Services with permission from Pivotal Sources....